U.S. Draft Executive Order “More Bark Than Bite”: Will Chinese Innovative-Drug BD Deals Still Benefit Long-Term?China Finance Tech in China3SBio, Biotech, CSPC Pharmaceutical Group, FDA, GSK, Hebo Pharmaceuticals, Hengrui, Pharmaceuticals September 12, 2025
